| III-27 Elisa Borella Vaborem pharmacokinetics and dose rationale in children |
| III-28 Elisa Borella Oritavancin pharmacokinetics and dose rationale in children |
| III-29 Salvatore D'Agate Model-based evaluation of beta-lactams in neonatal and paediatric sepsis |
| III-30 Eva Degraeuwe Population pharmacokinetic modeling of lisinopril at steady-state in hypertensive pediatric patients with mild to moderate renal impairment |
| III-31 Esther Encinas Simulation of systemic exposure after multiple ocular administration of bilastine ophthalmic solution for safety assessment in children |
| III-32 Aline Engbers Lack of pharmacokinetic interaction between doxapram and caffeine for the treatment of preterm infants with apnea |
| III-33 Alan Faraj Phase-3 dose selection of marzeptacog alfa (activated) in children enabled by model-informed drug development techniques |
| III-34 Kinga Fiebig Prospective evaluation of a novel model-based dosing guideline for gentamicin in preterm and term neonates |
| III-35 Anthony Gebhart A semi-physiologically based pharmacokinetics approach to predict hepatic and gut wall intrinsic clearances of midazolam in pediatric patients: preliminary results filling the gap between preterm neonates and infants above 1 year |
| III-36 Iztok Grabnar Pharmacokinetic-pharmacodynamic model of fentanyl sedation in children with severe acute bronchiolitis |
| III-37 Ana-Marija Grisic Population pharmacokinetic model of avelumab in a pediatrics population |
| III-38 Soumya Perinparajah A Novel Mechanistic Mathematical Model for CD19+ B Cell Reconstitution after Paediatric Haematopoietic Stem Cell Transplantation |
| III-39 Maša Roganović Population pharmacokinetic modelling of cyclosporine in paediatric kidney transplant patients using routine TDM data |
| III-40 Rajendra Singh Determination of the individual pharmacokinetic exposure parameter uncertainty to support of pediatric exposure-response trial design |
| III-41 Rajendra Singh Population pharmacokinetic analysis of deutetrabenazine (AUSTEDO) in children and adolescents with Tourette Syndrome |
| III-42 Erik Sjögren Lumenfantrine Exposure in Malnourished Children: PBPK modeling applied for Predictions and Dose Adjustments |
| III-43 Tomás Sou Caplacizumab Model-Based Dosing Recommendations In Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura |
| III-44 Marinda van de Kreeke Quantifying requirements for additional sedatives in critically-ill children using a repeated time to event analysis |
| III-45 Louvina van der Laan Pharmacokinetics of para-aminosalicylic acid in children treated for multidrug-resistant tuberculosis. |
| III-46 Yunjiao Wu Pre- and postnatal maturation are important for fentanyl exposure in preterm and term newborns: a pooled population pharmacokinetic study |
